專利條例第 20 條發表的指定專利申請記錄請求 Requests to Record Designated Patent Applications Published Under Section 20 of the Patents Ordinance
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
香港知識產權公報hong Kong Intellectual Property
香港知識產權公報 Hong Kong Intellectual Property Journal 2009年9月18日 18 September 2009 公報編號 Journal No.: 337 公布日期 Publication Date: 18-09-2009 分項名稱 Section Name: 目錄 Contents 目錄 Contents 根據專利條例第 20 條發表的指定專利申請記錄請求 Requests to Record Designated Patent Applications published under section 20 of the Patents Ordinance 1. 按國際專利分類排列 Arranged by International Patent Classification 2. 按發表編號排列 Arranged by Publication Number 3. 按申請編號排列 Arranged by Application Number 4. 按申請人姓名/名稱排列 Arranged by Name of Applicant 根據專利條例第 27 條發表批予標準專利 Granted Standard Patents published under section 27 of the Patents Ordinance 1. 按國際專利分類排列 Arranged by International Patent Classification 2. 按發表編號排列 Arranged by Publication Number 3. 按申請編號排列 Arranged by Application Number 4. 按專利所有人姓名/名稱排列 Arranged by Name of Proprietor 1/341 公報編號 Journal No.: 337 公布日期 Publication Date: 18-09-2009 分項名稱 Section Name: 目錄 Contents 根據專利條例第 118 條發表批予短期專利 Granted Short-term Patents published under section 118 of the Patents Ordinance 1. 按國際專利分類排列 Arranged by International Patent Classification 2. 按發表編號排列 Arranged by Publication Number 3. 按申請編號排列 Arranged by Application Number 4. 按專利所有人姓名/名稱排列 Arranged by Name of Proprietor 根據專利條例(第 514 章)公布的其他公告 Other Notices Published under the Patents Ordinance (Cap. 514) 根據專利條例第 20 條發表後撤回,當作已予撤回或被拒的申請 Applications Withdrawn, Deemed to have been Withdrawn, or Refused, after Publication under section 20 of the Patents Ordinance 根據專利條例第 39 條,標準專利因未繳續期費而停止有效 Standard Patents Ceased through Non-payment of Renewal Fees under section 39 of the Patents Ordinance 根據專利條例第 39(1)(b)條,標準專利 -
2004 IEEE 15Th INTERNATIONAL SYMPOSIUM on PERSONAL, INDOOR and MOBILE RADIO COMMUNICATIONS
2004 IEEE 15th INTERNATIONAL SYMPOSIUM ON PERSONAL, INDOOR AND MOBILE RADIO COMMUNICATIONS PIMRC 2004 BARCELONA, Spain 5-8, September 2004 Hotel Princesa Sofia Proceedings Volume 3 of 4 TIB/UB Hannover 89 126 450 447 Table of Contents Volume III j Conference Co-chairs' Message xix ! Organizing Comitee xxi • Technical Program Comitee xxii i Reviewing Comitee xxiv Tuesday, September 7th, 2004 SESSION TuePmOR7: Mobile Internet (2) FAST-HANDOFF SCHEMES FOR APPLICATION LAYER MOBILITY MANAGEMENT 1527 Ashutosh Dutta, Sunil Madhani, Wai Chen, Telcordia Technologies, USA; Onur Altintas, Toyota InfoTechnology Center, USA; and Henning Schulzrinne, Columbia University, USA PERFORMANCE ANALYSIS OF IP PAGING AND POWER SAVE MODE IN IP-BASED MOBILE NETWORKS 1533 Yun Won Chung, Jee Hyeon Na, Yeong Jin Kim, Electronics and Telecommunications Research Institute, Korea; and Ho-Shin Cho, Kyungpook National University, Korea MODELING USER MOBILITY FOR RELIABLE PACKET DELIVERY IN MOBILE IP NETWORKS 1538 Jiunn Ru Lai and Wanjiun Liao, National Taiwan University, Taiwan CROSS-LAYER ANALYSIS OF WIRELESS TCP/ARQ SYSTEMS OVER CORRELATED CHANNELS 1542 Yi Wu, Zhisheng Niu and Junli Zheng, Department of Electronic Engineering, Tsinghua University,, China A COST-AWARE CONTROL SCHEME FOR EFFICIENT AUTHENTICATION IN WIRELESS NETWORKS . 1548 Wei Liang, NC State University, United States; and Wenye Wang, IEEE Member, United States SESSION TuePmOR8: Wireless Propagation (1) MULTI-ENVIRONMENT RADIO PREDICTIONS INVOLVING AN IN-BUILDING WLAN NETWORK AND OUTDOOR UMTS BASE STATIONS -
Concert Program
CONCERT PROGRAM 1 Концертная программа Санкт-ПетербургСкая гоСударСтвенная конСерватория им. н. а. римСкого-корСакова THE ST. PETERSBURG N. A. RIMSKY-KORSAKOV STATE CONSERVATORY Санкт-Петербург ST. PETERSBURG 2014 2 УчреДитель FOUNDER Владимир СТОПИЧЕВ Vladimir STOPICHEV декан оркестрового факультета Dean of the Orchestra Department Санкт-Петербургская государственная The St. Petersburg N. A. Rimsky-Korsakov леонид ЗАЙЧИК Leonid ZAICHIK консерватория им. Н. А. Римского-Корсакова State Conservatory декан фортепианного факультета Dean of the Piano Department Юрий ЛАПТЕВ Yury LAPTEV При поддержке With support from декан вокально-режиссерского факультета Dean of the Vocal and Directing Department Министерства культуры Российской Федерации the Ministry of Culture of the Russian Federation олег ШАРОВ Oleg SHAROV Комитета по культуре Санкт-Петербурга the St. Petersburg Committee for Culture декан факультета народных инструментов Dean of the Folk Instruments Department Комитета по внешним связям Санкт-Петербурга the Committee for External Relations of St. Petersburg наталья АГАБаБоВа Natalia AGABABOVA декан по работе с иностранными учащимися Chief of the Dean`s Office for International Students ирина БОГАЧЕВа Irina BOGACHEVA заведующая кафедрой сольного пения Head of the Recital Division ПОПЕЧИТЕЛЬСКий СоВет THE BOARD OF TRUSTEES екатерина мУрина Ekaterina MURINA заведующая кафедрой специального фортепиано Head of the Special Piano Division ГЕНЕРАЛЬНЫЕ КОНСУльСтВа: THE CONSULATES GENERAL OF: александр ТИТОВ Alexander TITOV Соединенных Штатов Америки в Санкт-Петербурге the United States in St. Petersburg заведующий кафедрой оперно-симфонического Head of the Opera and Symphony дирижирования Conducting Division Федеративной Республики Германия в Санкт-Петербурге the Federal Republic of Germany in St. Petersburg антон ТАНОНОВ Anton TANONOV Азербайджанской Республики в Санкт-Петербурге the Republic of Azerbaijan in St. -
(R&D) Tax Credit
Report toThe the Pennsylvania Pennsylvania Department of General Revenue Assembly Bureau of Research on the Research and Development (R&D) Tax Credit The Pennsylvania Department of Revenue Bureau of Research March 15, 2012 Pennsylvania Research and Development Tax Credit Page 1 of 14 The Pennsylvania R&D Tax Credit Statute On May 7, 1997, Act 7 of 1997 created the Pennsylvania research and development (R&D) tax credit. The R&D tax credit provision became Article XVII-B of the Tax Reform Code of 1971 (TRC). The intent of the R&D tax credit was to encourage taxpayers to increase R&D expenditures within the Commonwealth in order to enhance economic growth. The terms and concepts used in the calculation of the Commonwealth’s R&D tax credit are based on the federal government’s R&D tax credit definitions for qualified research expense.1 For R&D tax credits awarded between December 1997 and December 2003, Act 7 of 1997 authorized the Department of Revenue (Department) to approve up to $15 million in total tax credits per fiscal year. Additionally, $3 million of the $15 million was set aside for “small” businesses, where a “small business” is defined as a “for-profit corporation, limited liability company, partnership or proprietorship with net book value of assets totaling…less than five million dollars ($5,000,000).” Over the years, several changes have been made to the R&D tax credit statute. Table 1 lists all of the acts that have changed the R&D tax credit statute, along with the applicable award years, the overall tax credit cap and the “small” business set aside. -
February 19, 2014
CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS Oversight Committee Meeting February 19, 2014 CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS Summary Overview of the February 19, 2014, Oversight Committee Meeting Please find enclosed the meeting packet for the next meeting of the CPRIT Oversight Committee to be held on Wednesday, February 19, 2014, at 10:00 AM. This summary overview of major agenda items provides background on key issues for Committee consideration. CEO Report Wayne Roberts will present the CEO’s report and address issues assigned by the Oversight Committee at the January 24th meeting including reconstituting the University Advisory Committee (UAC) and proposed dashboard metrics for the agency. Chief Scientific Officer Program Portfolio Presentation and Grant Award Recommendations Dr. Margaret Kripke will present the Program Integration Committee’s recommendations for scientific research awards. The research continuation grant recommendations are the first grant applications to be considered under the “new” review process set out by SB 149. SB 149 changed the way that grant recommendations are formally approved. A vote by two-thirds of the Oversight Committee that are present and voting (i.e. not recused because of a conflict of interest) is required to approve each funding recommendation. If two-thirds of the Oversight Committee does not vote to approve an award recommendation, then a statement explaining the reason for not following the PIC’s recommendation must be included in the meeting minutes. Product Development Officer Program Portfolio Presentation and Grant Award Recommendations Kristen Doyle, acting Product Development Officer, and Dr. Jack Geltosky, CPRIT’s Product Development Review Council Chair, will discuss CPRIT’s product development portfolio and present the Chief Executive Officer’s recommendations for product development grant awards. -
Drug Repositioning: Extracting Added Value from Prior R&D Investments
Drug Repositioning: Extracting Added Value from Prior R&D Investments Hermann A.M. Mucke, Ph.D. InsightPharmaReports.com Drug Repositioning: Extracting Added Value from Prior R&D Investments Hermann A.M. Mucke, Ph.D. Published in July 2010 by Cambridge Healthtech Institute • www.InsightPharmaReports.com • Reproduction prohibited i Insight Pharma Reports is a division of Cambridge Healthtech Institute, a world leader in life science information and analysis through conferences, research reports, and targeted publications. Insight Pharma Reports focus on pharmaceutical R&D—the technologies, the companies, the markets, and the strategic business impacts. They regularly feature interviews with key opinion leaders; surveys of the activities, views, and plans of individuals in industry and nonprofit research; and substantive assessments of technologies and markets. Managers at the top 50 pharma companies, the top 100 biopharma companies, and the top 50 vendors of tools and services rely on Insight Pharma Reports as a trusted source of balanced and timely information. Related Report Data Mining in Drug Development and Translational Medicine by Hermann A.M. Mucke, Ph.D. General Manager: Alfred R. Doig, Jr. 781-972-1348, [email protected] Editorial Operations Director: Laurie Sullivan 781-972-1353, [email protected] Design Director: Tom Norton 781-972-5440, [email protected] Production Director: Ann Handy 781-972-5493, [email protected] Marketing Manager: James Prudhomme 781-972-5486, [email protected] Customer Service: Rose LaRaia 781-972-5444, [email protected] Corporate Subscriptions: David Cunningham 781-972-5472, [email protected] Global Report Sales: Jack Valeri 781-972-1355, [email protected] Insight Pharma Reports, 250 First Ave., Suite 300, Needham, MA 02494 www.InsightPharmaReports.com ii • www.InsightPharmaReports.com • Reproduction prohibited Drug Repositioning: Extracting Added Value from Prior R&D Investments Hermann A.M. -
(R&D) Tax Credit
Report to theThe Pennsylvania Pennsylvania Department General of Revenue Assembly Bureau of Research on the Research and Development (R&D) Tax Credit The Pennsylvania Department of Revenue Bureau of Research March 15, 2010 Pennsylvania Research and Development Tax Credit Page 1 of 15 The Pennsylvania R&D Tax Credit Statute As part of the Fiscal Year 2009-10 budget, Act 48 of 2009 reduced the amount of tax credits available under several tax credit programs that can be awarded during the following two years. Act 48 reduced the total amount of R&D tax credit available in FY 2009-10 from $40 million to $20 million and in FY 2010-11 from $40 million to $18 million. Starting in FY 2011-12, the total amount of R&D tax credit the Department can award returns to $40 million per year. ******** On May 7, 1997, Act 7 of 1997 created the Pennsylvania research and development (R&D) tax credit. The R&D tax credit provision became Article XVII-B of the Tax Reform Code of 1971 (TRC). The intent of the R&D tax credit was to encourage taxpayers to increase R&D expenditures within the Commonwealth in order to enhance economic growth. The terms and concepts used in the calculation of the Commonwealth’s R&D tax credit are based on the federal government’s R&D tax credit definitions for qualified research expense.1 Over the years, several changes have been made to the R&D tax credit statute. On December 23, 2003, Governor Edward G. Rendell signed Act 46 of 2003 into law. -
יומן הפטנטים והמדגמים Patents and Designs Journal
י /' התשס"ח 5/2008 רשומות ISRAEL STATE RECORDS ו' באב התשס"ח August 7, 2008 יומן הפטנטים והמדגמים PATENTS AND DESIGNS JOURNAL פטנטים עמוד PATENTS Page בקשות שהוגשו Applications filed 1507 בקשות שקובלו Applications accepted 1775 פטנטים שניתנו Patents granted 1992 פטנטים שחודשו Patents renewed 1993 פטנטים שתוקפם פקעו Patents not in force 1995 פטנטים שחודשו לעשרים שנה Patents renewed for 20 years 1996 פטנטים שפג תוקפם Patents expired 1997 הודעות Notices 1998 שינויים בפרטים רשומים Changes in particulars entered בפנקס in register 2001 תיקוני טעויות Corrigenda 2002 מפתחות לבקשות שקובלו Indices of applications accepted i מדגמים DESIGNS מדגמים שנרשמו Designs registered 2004 מדגמים שחודשו Designs renewed 2017 מדגמים שבוטלו Designs void 2018 ו' באב התשס"ח – August 7, 2008 1507 ידיעות כלליות מכתבים, מסמכים, וכו' בענייני פטנטים ומדגמים יש לשלוח אל: רשם הפטנטים והמדגמים, רח' הסדנא 4, ירושלים לשכת הפטנטים נמצאת ברח' הסדנא 4, תלפיות, ירושלים והיא פתוחה לציבור בימי חול שאינם ערבי שבת או מועד בין השעות 8:30 ו - 12:30. לשכת הפטנטים מספקת תצלומים של פירוטים ושרטוטים במחיר של 2.50 שקלים בעד כל עמוד או חלק ממנו. אגרות ללשכת הפטנטים מתקבלות אך ורק על ידי תשלום לחשבון הלשכה בבנק הדואר מס' 0-24145-2. יש להציג קבלת בנק הדואר ללשכה יחד עם הבקשה לפעולה שעבורה האגרה שולמה. GENERAL INFORMATION Letters, documents, etc. concerning Patents and Designs should be addressed to: The Commissioner of Patents and Designs, 4 Hasadnah St., Jerusalem The Patent Office is located at 4 Hasadnah St., Talpiot, Jerusalem and is open to the public on weekdays, except on Fridays or on the eves of holydays, from 08:30 to 12:30 hrs. -
Aes Corporation
THE AES CORPORATION THE AES CORPORATION The global power company A Passion to Serve A Passion A PASSION to SERVE 2000 ANNUAL REPORT ANNUAL REPORT THE AES CORPORATION 1001 North 19th Street 2000 Arlington, Virginia 22209 USA (703) 522-1315 CONTENTS OFFICES 1 AES at a Glance AES CORPORATION AES HORIZONS THINK AES (CORPORATE OFFICE) Richmond, United Kingdom Arlington, Virginia 2 Note from the Chairman 1001 North 19th Street AES OASIS AES TRANSPOWER Arlington, Virginia 22209 Suite 802, 8th Floor #16-05 Six Battery Road 5 Our Annual Letter USA City Tower 2 049909 Singapore Phone: (703) 522-1315 Sheikh Zayed Road Phone: 65-533-0515 17 AES Worldwide Overview Fax: (703) 528-4510 P.O. Box 62843 Fax: 65-535-7287 AES AMERICAS Dubai, United Arab Emirates 33 AES People Arlington, Virginia Phone: 97-14-332-9699 REGISTRAR AND Fax: 97-14-332-6787 TRANSFER AGENT: 83 2000 AES Financial Review AES ANDES FIRST CHICAGO TRUST AES ORIENT Avenida del Libertador COMPANY OF NEW YORK, 26/F. Entertainment Building 602 13th Floor A DIVISION OF EQUISERVE 30 Queen’s Road Central 1001 Capital Federal P.O. Box 2500 Hong Kong Buenos Aires, Argentina Jersey City, New Jersey 07303 Phone: 852-2842-5111 Phone: 54-11-4816-1502 USA Fax: 852-2530-1673 Fax: 54-11-4816-6605 Shareholder Relations AES AURORA AES PACIFIC Phone: (800) 519-3111 100 Pine Street Arlington, Virginia STOCK LISTING: Suite 3300 NYSE Symbol: AES AES ENTERPRISE San Francisco, California 94111 Investor Relations Contact: Arlington, Virginia USA $217 $31 Kenneth R. Woodcock 93% 92% AES ELECTRIC Phone: (415) 395-7899 $1.46* 91% Senior Vice President 89% Burleigh House Fax: (415) 395-7891 88% 1001 North 19th Street $.96* 18 Parkshot $.84* AES SÃO PAULO Arlington, Virginia 22209 Richmond TW9 2RG $21 Av. -
RUSSIAN, SOVIET & POST-SOVIET CONCERTOS a Discography Of
RUSSIAN, SOVIET & POST-SOVIET CONCERTOS A Discography of CDs and LPs Prepared by Michael Herman Edited by Stephen Ellis Composers H-P GAGIK HOVUNTS (see OVUNTS) AIRAT ICHMOURATOV (b. 1973) Born in Kazan, Tatarstan, Russia. He studied clarinet at the Kazan Music School, Kazan Music College and the Kazan Conservatory. He was appointed as associate clarinetist of the Tatarstan's Opera and Ballet Theatre, and of the Kazan State Symphony Orchestra. He toured extensively in Europe, then went to Canada where he settled permanently in 1998. He completed his musical education at the University of Montreal where he studied with Andre Moisan. He works as a conductor and Klezmer clarinetist and has composed a sizeable body of music. He has written a number of concertante works including Concerto for Viola and Orchestra No1, Op.7 (2004), Concerto for Viola and String Orchestra with Harpsicord No. 2, Op.41 “in Baroque style” (2015), Concerto for Oboe and Strings with Percussions, Op.6 (2004), Concerto for Cello and String Orchestra with Percussion, Op.18 (2009) and Concerto for Piano and Orchestra, Op 40 (2014). Concerto Grosso No. 1, Op.28 for Clarinet, Violin, Viola, Cello, Piano and String Orchestra with Percussion (2011) Evgeny Bushko/Belarusian State Chamber Orchestra ( + 3 Romances for Viola and Strings with Harp and Letter from an Unknown Woman) CHANDOS CHAN20141 (2019) 3 Romances for Viola and Strings with Harp (2009) Elvira Misbakhova (viola)/Evgeny Bushko/Belarusian State Chamber Orchestra ( + Concerto Grosso No. 1 and Letter from an Unknown Woman) CHANDOS CHAN20141 (2019) ARSHAK IKILIKIAN (b. 1948, ARMENIA) Born in Gyumri Armenia. -
Collaborative Drug Discovery's 10 Anniversary Community Meeting
Collaborative Drug Discovery’s 10th Anniversary Community Meeting April 4th, 2014 8am-6pm UCSF Mission Bay Conference Center 1675 Owens St. San Francisco, CA 94158 Please use this Twitter hashtag for the event: #CDDx14 Agenda 7:45 Registration - refreshments in Foyer and Exhibition room 8:15 Opening Remarks - with UCSF Host, Stephanie Robertson and CDD CEO, Barry Bunin Collaborative Workflow: Basic and Advanced Use Cases of CDD Vault 8:20 Charlie Weatherall (CDD) & Anna Spektor (CDD) 9:10 Morning Sessions - moderated by Sylvia Ernst (CDD) The Rockefeller University Compound Screening Library 9:15 J. Fraser Glickman (Rockefeller University) Recent Progress in De-Orphanization of Nuclear Receptors 9:40 Ruo Steensma (Orphagen Pharmaceuticals) 10:05 Morning Break - located in the Foyer and Exhibition room Large small molecules in a Small large molecule world 10:35 Leanna Staben (Genentech) Linking the Molecular Structure of Medicines to their Biological Effects 11:00 Bob Volkmann (Systamedic & Mnemosyne Pharmaceuticals) Panel: Externalized Research - What Makes a Good Partnership? Wisdom from Experts 11:25 Who've "Been There - Done That," moderated by Sylvia Ernst (CDD) 11:50 Lunch - boxed lunches in the Foyer and Exhibition room Optional: “What if CDD had...” provide feedback to our product team (12:35) Kellan Gregory (CDD) 10 Years Evolving Our Collaborative Drug Discovery Vaults 1:05 Barry Bunin (CDD) CDD Vault: Noteworthy recent enhancements and a preview of things to come 1:30 David Blondeau (CDD) & Kellan Gregory (CDD) 2:20 Afternoon sessions - moderated Christopher Lipinski The Tuberculosis Drug Accelerator: A New Paradigm For Drug Discovery 2:25 Jerry Shipps (Tuberculosis Drug Accelerator) The role of NIAID in the development of therapeutics for Infectious Diseases 2:50 Martin John Rogers (NIAID) 3:15 Afternoon Break - located in the Foyer and Exhibition Room Targeting the Immunoproteasome 3:40 Dustin L. -
Årsredovisning Med Information Från Form 20-F 2008 Inledning 2
ASTRAZENECA – ÅRSREDOVISNING MED INFORMATION FRÅN FORM 20-F 2008 INLEDNING 2 AstraZeneca och året i korthet 2 Utvecklingen i sammandrag 2 Ordföranden har ordet 4 Koncernchefens översikt 5 FÖRVALTNINGSBERÄTTELSE 8 FÖRVALTNINGSBERÄTTELSE 8 Inledning 8 Omvärldsanalys 9 Strategi, mål och mätetal 12 > Mäta våra resultat 14 > Vår utveckling – Ekonomiska och övriga nyckeltal 15 Resurser, kompetenser och möjligheter 16 > Läkemedel 16 > Forskning och utveckling 17 > Forsknings- och utvecklingsportfölj den 29 januari 2009 22 BOKSLUT 98 > Försäljning och marknadsföring 25 >6 Immateriella rättigheter 2 > Varuförsörjning och produktion 27 > Medarbetare 28 Ekonomisk översikt 31 > Rapporteringsprinciper 31 > Verksamhetsbakgrund och viktiga händelser 2008 32 > Kortfattad analys av perioden jan–dec 2008 33 > Finansiell ställning , inklusive kassafl öde och likviditet – 2008 35 > Omstrukturerings- och synergi- RAPPORT OM ERSÄTTNINGAR 174 kostnader 36 > Kapital och aktieavkastning 37 > Framtidsutsikter 37 > Kortfattad analys av perioden jan–dec 2007 38 > Finansiell ställning, inklusive kassafl öde och likviditet – 2007 40 > Hantering av fi nansiella risker 41 > Viktiga redovisningsprinciper och bedömningar 43 > Övrig redovisnings information 47 YTTERLIGARE INFORMATION 190 VIKTIG INFORMATION FÖR LÄSARE som var tillgänglig vid utarbetandet av denna Användandet av redovisad utveckling, fasta AV DENNA REDOVISNING årsredovisning med information från Form 20-F och valutakurser och ekonomiska mått för kärn- företaget åtar sig inget ansvar för att uppdatera dessa verksamheten framåtriktade kommentarer. Vi identifi erar framåtriktade I förvaltningsberättelsen och i avsnittet Utvecklingen i Risker beträffande framåtriktade kommentarer kommentarer genom ord som till exempel ”förutse”, sammandrag på sidorna 2 och 3 hänvisas till följande Syftet med denna årsredovisning med information från ”tror”, ”förväntar”, ”avser” och snarlika uttryck i sådana mått: Form 20-F är att tillhandahålla information till företagets kommentarer.